Condition: Locally Advanced Cervical Cancer · Sponsor: AstraZeneca
This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIA to IVA cervical cancer) who have not progressed following platinum-based CCRT.
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
Always discuss trial participation with your own doctor first.
| Research Site | Birmingham, Alabama, United States | Withdrawn |
| Research Site | Phoenix, Arizona, United States | Withdrawn |
| Research Site | Tucson, Arizona, United States | Withdrawn |
| Research Site | Little Rock, Arkansas, United States | Withdrawn |
| Research Site | La Jolla, California, United States | Withdrawn |
| Research Site | West Hollywood, California, United States | Withdrawn |
| Research Site | Atlanta, Georgia, United States | Withdrawn |
| Research Site | Augusta, Georgia, United States | Withdrawn |
| Research Site | Savannah, Georgia, United States | Terminated |
| Research Site | Melrose Park, Illinois, United States | Withdrawn |
| Research Site | Indianapolis, Indiana, United States | Withdrawn |
| Research Site | New Orleans, Louisiana, United States | Withdrawn |
+ 193 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06079671